поучительные мультфильмы для детей онлайн бесплатно
Главное меню:
Интересное
поучительные мультфильмы для детей онлайн бесплатно, ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment, Enjaymo: Uses, Dosage, Side Effects & Warnings - Drugs.com, LABEL - accessdata.fda.gov, ENJAYMO® (sutimlimab-jome) | Dosing and Administration, ENJAYMO- sutimlimab-jome injection, solution, concentrate - DailyMed, Enjaymo - European Medicines Agency (EMA), Enjaymo: Uses, Dosage, Side Effects & Warnings - en.
OY=DLzmdm!ާꕊ_Gnw.S.؟;c\ 20~{ |o0~{sL?~\6{ݡY6vf-m|gcm\_y F܀LG 7ܜk1t(yԆq+`rהq[a$l)y1?g;cfW1nݟ 90.vnaP,֯[N=xIY Z W7-M1^"l6K|$W@Yg:\H鸞aY?")691Hz{'[)v*|NH|vvJӄ0[.Ve Cs,>Ӿ{$.ޫ3O:V3pw_ֶ%wh>.W MB|*,}"}"[Ml'NOtz|;_sAdӔG 3ҹoR&|7"_Ra;}uiv7#|xI{rE-R:^ѓ$ u&P &j.Gonf, ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion., Enjaymo side effects Enjaymo can cause serious side effects, including: See information important. Infusion-related reactions. Treatment with Enjaymo may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your infusion if you have an infusion-related reaction, and will treat your symptoms if .
The infusion catheter and tubing should be primed with the dosing solution immediately before infusion and flushed immediately following completion of the infusion with a sufficient quantity (approximately 20 mL) of sterile 0.9% Sodium Chloride Injection, USP. If the ENJAYMO infusion solution is not used immediately, store refrigerated at 36°F to 46°F (2°C to 8°C)., The recommended dosing regimen for adults with Cold Agglutinin Disease (CAD) consists of an initial dose and a dose 1 week later, followed by 1 dose every 2 weeks. ENJAYMO is for IV infusion only., NDC 55292-820-01 - Rx only - Enjaymo® (sutimlimab-jome) Injection - 1,100 mg/22 mL (50 mg/mL) For Intravenous Infusion - Attention Pharmacist: Each patient is required to receive the - enclosed Medication , Enjaymo is given as an infusion (drip) into a vein lasting 1 or 2 hours. There are two dose levels recommended dependent on the patient’s weight. The treatment is given once a week for the first 2 weeks and then every 2 weeks. Patients should be monitored during and after the infusion for certain side effects related to the infusion., It is not known if this medicine is safe and effective in children. Enjaymo side effects Enjaymo can cause serious side effects, including: See information important. Infusion-related reactions. Treatment with Enjaymo may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening., What is Enjaymo for cold agglutinin disease? Enjaymo (sutimlimab-jome) is an infusion therapy approved to reduce hemolysis, or red blood cell destruction, in adults with cold agglutinin disease (CAD)..